METTL3 and leukemia: UZH1a is 100 times more potent than UZH1b in terms of METTL3 inhibition and m6A reduction.[130] With a goal of discovering more potent METTL3 inhibitors, this group developed UZH2 (1,4,9‐triazapriro[5,5]undecan‐2‐one) which has higher potency and more favorable ADME (absorption, distribution, metabolism, and excretion) features.[131] Another group developed a potent METTL3 inhibitor, STM2457, and tested its efficacy against leukemia.